Myriad Genetics, Inc. (NASDAQ: MYGN) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $531M. The Maz Rating grades it against the other companies in its sector.
Myriad Genetics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.54, Myriad Genetics, Inc. trades at 0.7x sales and 2.0x book value. Over the last twelve months it generated about $806M of revenue and a net loss of $131M. It runs a gross margin of 68.3%, an operating margin of -14.3% and a net margin of -16.1%. It shows return on equity of -40.4%, return on invested capital of -24.0% and a free cash flow yield of -6.6%. On the balance sheet: a debt-to-equity ratio of 0.78 and a current ratio of 1.98. Over the past 52 weeks the share price ranged from $2.74 to $8.09, with a beta of 1.61.
Myriad Genetics, Inc. does not currently pay a dividend.
37 Wall Street analyst ratings cover the stock: 8 Buy, 22 Hold and 7 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Myriad Genetics, Inc. (MYGN) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 28.7% / 30% · (Cash+Inv) / Mkt Cap (36m) 25.4% / 30% · Interest income / Revenue 0.30% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 28.7% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 25.4% / 33% · Receivables / Mkt Cap (36m) 25.0% / 49% · Interest income / Revenue 0.30% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 28.7% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 25.4% / 33.33% · Receivables / Mkt Cap (24m) 25.0% / 33.33% · Interest income / Revenue 0.30% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 18.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 18.9% / 33.33% · Receivables / Avg Assets (4Q) 17.3% / 33.33% · Interest income / Revenue 0.30% / 5% | Pass |
| FTSE | Debt / Total Assets 19.9% / 33.33% · (Cash+ST Inv) / Total Assets 17.6% / 33.33% · (Cash+Recv) / Total Assets 34.9% / 33.33% · Interest income / Revenue 0.30% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Myriad Genetics, Inc. (MYGN) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Myriad Genetics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.30% of each dividend: Myriad Genetics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.